[go: up one dir, main page]

DK1311272T3 - New methods using cholinesterase inhibitors - Google Patents

New methods using cholinesterase inhibitors

Info

Publication number
DK1311272T3
DK1311272T3 DK01922272T DK01922272T DK1311272T3 DK 1311272 T3 DK1311272 T3 DK 1311272T3 DK 01922272 T DK01922272 T DK 01922272T DK 01922272 T DK01922272 T DK 01922272T DK 1311272 T3 DK1311272 T3 DK 1311272T3
Authority
DK
Denmark
Prior art keywords
cholinesterase inhibitors
new methods
cholinesterase
inhibitors
donepezil
Prior art date
Application number
DK01922272T
Other languages
Danish (da)
Inventor
Raymond Pratt
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Application granted granted Critical
Publication of DK1311272T3 publication Critical patent/DK1311272T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to cholinesterase inhibitors such a donepezil for the treatment of cognitive impairments associated with or caused by chemotherapy
DK01922272T 2000-03-03 2001-03-05 New methods using cholinesterase inhibitors DK1311272T3 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18674400P 2000-03-03 2000-03-03
US19761000P 2000-04-18 2000-04-18
US22078300P 2000-07-25 2000-07-25
US25922601P 2001-01-03 2001-01-03
PCT/US2001/007027 WO2001066114A1 (en) 2000-03-03 2001-03-05 Novel methods using cholinesterase inhibitors

Publications (1)

Publication Number Publication Date
DK1311272T3 true DK1311272T3 (en) 2007-02-26

Family

ID=27497683

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01922272T DK1311272T3 (en) 2000-03-03 2001-03-05 New methods using cholinesterase inhibitors

Country Status (11)

Country Link
US (7) US20020035128A1 (en)
EP (5) EP1311272B1 (en)
JP (1) JP2003525903A (en)
AT (1) ATE345803T1 (en)
AU (1) AU2001249091A1 (en)
CY (1) CY1107997T1 (en)
DE (1) DE60124730T2 (en)
DK (1) DK1311272T3 (en)
ES (1) ES2275670T3 (en)
PT (1) PT1311272E (en)
WO (1) WO2001066114A1 (en)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
US20030153598A1 (en) * 2000-07-25 2003-08-14 Raymond Pratt Methods for treating Parkinson's disease with cholinesterase inhibitors
DK1311272T3 (en) * 2000-03-03 2007-02-26 Eisai R&D Man Co Ltd New methods using cholinesterase inhibitors
EP1372620A2 (en) * 2001-03-15 2004-01-02 Saegis Pharmaceuticals Methods for restoring cognitive function following systemic stress
US20030060423A1 (en) * 2001-08-30 2003-03-27 Plata-Salaman Carlos R. Co-therapy for the treatment of dementia and associated behavioral manifestations comprising anticonvulsant derivatives and acetylcholinesterase inhibitors
AU2002340232A1 (en) * 2001-10-17 2003-04-28 Eisai Co., Ltd. Methods for treating substance abuse with cholinesterase inhibitors
WO2003061658A1 (en) * 2002-01-22 2003-07-31 Eisai Co., Ltd. Sigma receptor binder containing indanone derivative
US20030162770A1 (en) * 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
US20070053976A1 (en) * 2002-05-17 2007-03-08 Eisai R & D Management Co., Ltd. Novel combination of drugs as antidepressant
WO2004034963A2 (en) * 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
AU2003256644A1 (en) * 2002-07-22 2004-02-09 Duke University Cholinergic therapy for individuals with learning disabilities
US20040142970A1 (en) * 2002-11-01 2004-07-22 Kathryn Chung Treatment of hyperkinetic movement disorder with donepezil
ATE487492T1 (en) * 2003-02-27 2010-11-15 Eisai R&D Man Co Ltd PHARMACEUTICAL COMPOSITION FOR TREATING DRUG DEPENDENCE
HRP20160180T1 (en) * 2003-04-24 2016-03-25 Incyte Holdings Corp AZA SPIRO ALKANA DERIVATIVES AS METALOPROTEASE INHIBITORS
US9119846B2 (en) * 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
IL155666A (en) * 2003-04-29 2013-12-31 Neurim Pharma 1991 Composition for treating insomnia
MXPA05012614A (en) * 2003-05-23 2006-08-23 Sention Inc Methods for treating cognitive impairment and improving cognition.
AU2004247487B2 (en) 2003-06-17 2010-05-20 Pfizer Inc. N-pyrrolidin-3-YL-amide derivatives as serotonin and noradrenaline re-uptake inhibitors
JPWO2005027968A1 (en) * 2003-09-19 2007-11-15 エーザイ・アール・アンド・ディー・マネジメント株式会社 Down syndrome treatment
EP1776089A2 (en) * 2003-12-31 2007-04-25 Actavis Group hf Donepezil formulations
EP1743036A4 (en) * 2004-01-22 2008-07-02 Genaissance Pharmaceuticals Apoe genetic markers associated with age of onset of alzheimer's disease
JP2007519733A (en) * 2004-01-26 2007-07-19 コーテックス ファーマシューティカルズ インコーポレーティッド A method to enhance the stimulation of synaptic response induced by ampakine by cholinesterase inhibitors
JP2007519738A (en) * 2004-01-30 2007-07-19 アクソニクス，インコーポレイテッド How to treat complications of diabetes
WO2005089496A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
WO2005089502A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
WO2005089504A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20050272722A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
TW200533371A (en) * 2004-04-15 2005-10-16 Dainippon Pharmaceutical Co Medicament comprising a combination of an acetylcholinesterase inhibitor and a 5-substituted-3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative
US20060135507A1 (en) * 2004-08-13 2006-06-22 Osamu Yokoyama Therapeutic agent for overactive bladder involved in aging
US7718674B2 (en) * 2004-09-27 2010-05-18 Bridge Pharma, Inc. Methods of relieving neuropathic pain with the S-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine
US20060079558A1 (en) * 2004-09-27 2006-04-13 Bridge Pharma. Inc. R-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine and other dermal anesthetics
WO2006107860A2 (en) * 2005-04-04 2006-10-12 Eisai Co., Ltd. Dihydropyridine compounds and compositions for headaches
GB0605544D0 (en) * 2006-03-20 2006-04-26 Univ Nottingham Genetic Markers For Alzheimer Disease
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
US7910108B2 (en) * 2006-06-05 2011-03-22 Incyte Corporation Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
WO2008011161A2 (en) * 2006-07-21 2008-01-24 Bridge Pharma, Inc. Dermal anesthetic compounds
US8012994B1 (en) 2006-09-22 2011-09-06 Sevastyanov Victor V Method for the treatment of sensorineural hearing loss with donepezil hydrochloride (ARICEPT®)
KR101408488B1 (en) * 2006-12-01 2014-06-17 닛토덴코 가부시키가이샤 Method for prevention of discoloration with time of donepezil-containing skin adhesive preparation
CN101588802A (en) * 2006-12-01 2009-11-25 日东电工株式会社 Stabilized donepezil-containing adhesive patch
JP2010520154A (en) * 2007-03-05 2010-06-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 AMPA receptor antagonists and NMDA receptor antagonists for neurodegenerative diseases
JP2010524844A (en) * 2007-04-26 2010-07-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 Cinnamide compounds for dementia
EA017249B8 (en) * 2007-05-10 2013-01-30 Олбани Молекьюлар Рисерч, Инк. Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
EP2211911A4 (en) * 2007-10-31 2012-11-14 Alseres Pharmaceuticals Inc METHODS FOR DIAGNOSING AND MONITORING THE TREATMENT OF LEWY BODY DEMENTIA BY EVALUATING DOPAMINE CARRIER LEVELS
US20090156561A1 (en) * 2007-12-13 2009-06-18 Seed John C Use of Cholinesterase Inhibitors In Smoking Cessation
US8232402B2 (en) * 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
EP2288345B1 (en) 2008-04-18 2015-06-10 University College Dublin National University Of Ireland, Dublin Psycho-pharmaceuticals
EP2291181B9 (en) 2008-04-18 2013-09-11 University College Dublin National University Of Ireland, Dublin Captodiamine for the treatment of depression symptoms
US20090291127A1 (en) * 2008-05-21 2009-11-26 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
BRPI0912099A2 (en) * 2008-05-30 2015-10-06 Eisai R&D Man Co Ltd percutaneously absorbable preparation
CA2724502A1 (en) * 2008-05-30 2009-12-03 Nitto Denko Corporation Adhesive preparation containing donepezil, and package of the same
CA2733265A1 (en) * 2008-09-30 2010-04-08 Teikoku Pharma Usa, Inc. Transdermal extended-delivery donepezil compositions and methods for using the same
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
JP2012508768A (en) * 2008-11-13 2012-04-12 リンク・メディスン・コーポレーション Azaquinolinone derivatives and uses thereof
AU2010236734B2 (en) * 2009-04-13 2015-06-11 Theravance Biopharma R&D Ip, Llc 5-HT4 receptor agonist compounds for treatment of cognitive disorders
US20100178307A1 (en) * 2010-01-13 2010-07-15 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
CN102905532A (en) 2010-02-09 2013-01-30 约翰斯.霍普金斯大学 Methods and compositions for improving cognitive function
EP2366378A1 (en) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Sustained-release donepezil formulations
US20110251239A1 (en) 2010-04-07 2011-10-13 Eisai Inc. Combination therapy for the treatment of dementia
GR1007368B (en) 2010-05-27 2011-08-02 Alapis Α.Β.Ε.Ε., Drinkable pharmaceutical solutions for the treatment of dementia symptoms
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
WO2012071369A2 (en) 2010-11-24 2012-05-31 The Trustees Of Columbia University In The City Of New York A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
US20120225922A1 (en) 2011-03-04 2012-09-06 Qr Pharma Effective Amounts of (3aR)-1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo [2,3-b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing Neurodegeneration
WO2013109543A1 (en) * 2012-01-20 2013-07-25 The Board Of Trustees Of The Leland Stanford Junior University Small molecule cmklr1 antagonists in demyelinating disease
US9333202B2 (en) 2012-05-01 2016-05-10 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease
HK1215170A1 (en) 2012-11-14 2016-08-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
WO2014151959A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
WO2014152018A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York Octahydrocyclopentapyrroles, their preparation and use
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
ES2705247T3 (en) 2013-03-14 2019-03-22 Univ Columbia 4-phenylpiperidines, their preparation and use
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
CA2904767C (en) 2013-03-15 2022-06-21 Agenebio, Inc. Methods and compositions for improving cognitive function
US9359315B2 (en) 2013-09-10 2016-06-07 Arrien Pharmaceuticals Llc Substituted 2,3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis
BR112016025356B1 (en) 2014-04-30 2023-04-18 The Trustees Of Columbia University In The City Of New York SUBSTITUTED 4-PHENYLPIPERIDINE COMPOUNDS, COMPOSITIONS AND THEIR USES
TWI698436B (en) 2014-12-30 2020-07-11 美商佛瑪治療公司 Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors
MA41291A (en) 2014-12-30 2017-11-07 Forma Therapeutics Inc PYRROLOTRIAZINONE AND IMIDAZOTRIAZINONE DERIVATIVES AS UBIQUE-SPECIFIC PROTEASE INHIBITORS No. 7 (USP7) FOR THE TREATMENT OF CANCER
JP2018504432A (en) 2015-02-05 2018-02-15 フォーマ セラピューティクス，インコーポレイテッド Isothiazolopyrimidinone, pyrazolopyrimidinone and pyrrolopyrimidinone as ubiquitin-specific protease 7 inhibitors
EP3253765A1 (en) 2015-02-05 2017-12-13 Forma Therapeutics, Inc. Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
WO2016126926A1 (en) 2015-02-05 2016-08-11 Forma Therapeutics, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
EA034167B8 (en) 2015-05-22 2021-04-27 Эйджинбайо, Инк. Extended release pharmaceutical compositions of levetiracetam
EP3334425B1 (en) 2015-08-14 2020-12-16 QR Pharma Methods of treatment or prevention of acute brain or nerve injuries
US20180338950A1 (en) 2017-05-24 2018-11-29 Qr Pharma, Inc. Prevention or Treatment of Disease States Due to Metal Dis-Homeostasis Via Administration of Posiphen to Healthy or Sick Humans
WO2019084681A1 (en) 2017-10-30 2019-05-09 Montreal Heart Institute Methods of treating elevated plasma cholesterol
EP3810128B1 (en) * 2018-06-19 2022-08-03 Universidad Pablo de Olavide Compositions for treating and/or preventing protein-aggregation diseases
US12304897B2 (en) 2019-01-31 2025-05-20 Kyorin Pharmaceutical Co., Ltd. 15-PGDH inhibitors
CN114502154A (en) * 2019-07-16 2022-05-13 拉什大学医学中心 Use of benzoate-containing compositions for treating neurodegenerative diseases

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL74497A (en) * 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
US4826843A (en) * 1985-07-08 1989-05-02 Bristol-Myers Cerebral function enhancing diazinylpiperidine derivatives
FI95572C (en) * 1987-06-22 1996-02-26 Eisai Co Ltd Process for the preparation of a medicament useful as a piperidine derivative or its pharmaceutical salt
JP2777159B2 (en) * 1988-12-22 1998-07-16 エーザイ株式会社 Pharmaceuticals containing cyclic amine derivatives
JP3075566B2 (en) 1990-05-15 2000-08-14 エーザイ株式会社 Optically active indanone derivative
JP2965675B2 (en) 1990-11-21 1999-10-18 エーザイ株式会社 Method for producing (-)-1-benzyl-4-[(5,6-dimethoxy-1-indanone) -2-yl] methylpiperidine
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
HUT66324A (en) * 1991-07-29 1994-11-28 Warner Lambert Co Quinazoline derivatives as acetylcholinesterase inhibitors and pharmaceutical compositions containing them
SE9103752D0 (en) * 1991-12-18 1991-12-18 Astra Ab NEW COMPOUNDS
SI9720038B (en) 1996-06-07 2010-06-30 Eisai Co Ltd Polymorphs of donepezil hydrochloride and process for production
TW513409B (en) 1996-06-07 2002-12-11 Eisai Co Ltd Polymorphs of donepezil hydrochloride
WO1997046526A1 (en) 1996-06-07 1997-12-11 Eisai Co., Ltd. Stable polymorphs of donepezil (1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine) hydrochloride and process for production
WO1998007431A1 (en) * 1996-08-22 1998-02-26 New York University Cholinesterase inhibitors for treatment of parkinson's disease
JP4095676B2 (en) 1997-03-03 2008-06-04 エーザイ株式会社 Use of cholinesterase inhibitors to treat attention disorders
AU9454098A (en) * 1997-09-24 1999-04-12 Nova Molecular, Inc. Methods for increasing apoe levels for the treatment of neurodegenerative disease
ES2218869T3 (en) 1997-12-05 2004-11-16 Eisai Co., Ltd. DONEPEZIL POLYMORPHIC CRYSTALS AND A PROCESS FOR THE PRODUCTION OF SUCH CRYSTALS.
US6252081B1 (en) 1998-01-16 2001-06-26 Eisai Co., Ltd. Process for production of donepezil derivative
US6193993B1 (en) 1998-03-03 2001-02-27 Eisai Co., Ltd. Suppository containing an antidementia medicament
WO2000012135A1 (en) 1998-08-28 2000-03-09 Eisai Co., Ltd Medicinal compositions with relieved bitterness, etc.
IT1304904B1 (en) 1998-09-11 2001-04-05 Eisai Co Ltd ANTICOLINESTERASIC DERIVATIVES FOR THE TREATMENT OF FUNCTIONAL AND / OR ORGANIC SYNDROME
EP1086706B1 (en) 1999-03-31 2003-11-26 Eisai Co., Ltd. Stabilized compositions containing nootropic drugs
US20030153598A1 (en) * 2000-07-25 2003-08-14 Raymond Pratt Methods for treating Parkinson's disease with cholinesterase inhibitors
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
DK1311272T3 (en) * 2000-03-03 2007-02-26 Eisai R&D Man Co Ltd New methods using cholinesterase inhibitors
US20030144255A1 (en) 2000-03-06 2003-07-31 Bain Allen I Compositions for prevention and treatment of dementia
US20010036949A1 (en) 2000-05-09 2001-11-01 Coe Jotham Wadsworth Pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal
WO2003024456A1 (en) 2001-09-20 2003-03-27 Eisai Co., Ltd. Methods for treating and preventing migraines
WO2003024450A1 (en) 2001-09-20 2003-03-27 Eisai Co., Ltd. Methods for treating prion diseases
AU2002340232A1 (en) 2001-10-17 2003-04-28 Eisai Co., Ltd. Methods for treating substance abuse with cholinesterase inhibitors
GB2405336A (en) 2002-05-01 2005-03-02 Eisai Co Ltd Cholinesterase inhibitors to prevent injuries caused by chemicals
WO2004034963A2 (en) 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
US20040142970A1 (en) * 2002-11-01 2004-07-22 Kathryn Chung Treatment of hyperkinetic movement disorder with donepezil

Also Published As

Publication number Publication date
EP1311272A4 (en) 2003-05-21
US6576646B1 (en) 2003-06-10
EP2133078A1 (en) 2009-12-16
EP1311272A1 (en) 2003-05-21
EP2130538A1 (en) 2009-12-09
EP2140868A1 (en) 2010-01-06
DE60124730T2 (en) 2007-10-04
US20030040532A1 (en) 2003-02-27
US20050250812A1 (en) 2005-11-10
CY1107997T1 (en) 2013-09-04
ATE345803T1 (en) 2006-12-15
JP2003525903A (en) 2003-09-02
US6482838B2 (en) 2002-11-19
PT1311272E (en) 2007-02-28
US20020035129A1 (en) 2002-03-21
DE60124730D1 (en) 2007-01-04
US20020040038A1 (en) 2002-04-04
US20020035128A1 (en) 2002-03-21
US20040122051A1 (en) 2004-06-24
EP1311272B1 (en) 2006-11-22
EP2138177A1 (en) 2009-12-30
ES2275670T3 (en) 2007-06-16
US7563808B2 (en) 2009-07-21
US6689795B2 (en) 2004-02-10
WO2001066114A1 (en) 2001-09-13
AU2001249091A1 (en) 2001-09-17
US6458807B1 (en) 2002-10-01

Similar Documents

Publication Publication Date Title
DK1311272T3 (en) New methods using cholinesterase inhibitors
DE60319364D1 (en) SUBSTITUTED PYRROLINS AS KINASE INHIBITORS
UY26820A1 (en) DERIVATIVES OF CYCLOPENTIL-GLUTARAMIDE AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE
DE60323749D1 (en) SUBSTITUTED PYRROLINS AS KINASE INHIBITORS
DK1362047T3 (en) Indazolyl-substituted pyrroline compounds as kinase inhibitors
NO20035603D0 (en) Fluoropyrrolidines as dipeptidyl peptidase inhibitors
EA200300566A1 (en) APPLICATION OF CCI-779 AS ANTI-TUMOR MEDIA
ATE284388T1 (en) CYCLPENTANOINDOLES, MIXTURES CONTAINING SUCH COMPOUNDS AND TREATMENT METHODS
NO20031001L (en) Polyarylcarboxamides useful as lipid-lowering agents
ECSP034874A (en) BENZOILSULFONAMIDS AND SULFONYLBENZAMIDINS USED AS ANTITUMURAL AGENTS
MX2007002584A (en) Pyridyl inhibitors of hedgehog signalling.
BR0308452A (en) pharmaceutical compositions and methods of preparing pharmaceutical compositions
MY148479A (en) Piperidinyl-substituted isoquinolone derivatives
DE60334243D1 (en) PYRIDINE N-OXIDE COMPOUNDS ALSPHOSPHODIESTERASE-4-INHIBITORS
PL1742642T3 (en) Phosphonate analogs of hiv integrase inhibitor compounds
DE602004031372D1 (en) PROOF OF STAPHYLOCOCCUS
DK1421075T3 (en) Piperidine derivatives useful as CCR5 antagonists for the treatment of HIV
ECSP077270A (en) ACIDS OF TIAZOLO - NAFTILO
HN2008001934A (en) 18-methyl-19-nor-androst-4-en-17,17-spiro-esters (18-methyl-19-nor-20-espirox-4-en-3-ones), as well as pharmaceutical preparations containing them.
NO20025405D0 (en) Modulators for TNF-alpha signaling
DK1181294T3 (en) Novel derivatives and analogs of galanthamine
TW200605871A (en) Carboxamido opioid compounds
DE602004018811D1 (en) PYRROLIDINE HYDROGEN DERIVATIVES AS ANGIOGENESE INHIBITORS
EA200100930A1 (en) METHOD OF TREATMENT COPD
GB0207653D0 (en) Methods of using lamellar bodies for therapeutic purposes